Ann: Quarterly Activity Report and Appendix 4C for Q3 FY2024, page-4

I get that the VA opportunity is the big ticket item for this company, but given that's all still up in the air, I'd love to see some more short-term focus on the rollout across Australia and NZ where we already have deals in place.

AF previously said the company could be sustainable from Aus/NZ receipts alone, but the rollout is going much slower than they had initially forecast, and the numbers we're seeing show no indication of it covering the company costs any time soon. In previous quarterlies I defended the company's growing staff and admin costs on the basis that their team was expanding rapidly to cover their aggressive rollout in Aus (100 i-Med sites by Christmas last year was their self-set goal), but they've not delivered results.